News

Data show teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial
Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...
Targeted Oncology11h
Managing Dose Reductions With Bispecific Therapies in Myeloma
During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in ...
MedPage Today18h
The Basics of Multiple Myeloma - MedPage Today
Multiple myeloma is almost always preceded by an asymptomatic premalignant stage known as monoclonal gammopathy of undetermined significance (MGUS). About 1% of patients with MGUS progress to SMM ...
The American Journal of Managed Care20h
Advancing Frontline Therapy in Transplant-Eligible Myeloma and Emerging Trends in Smoldering Myeloma Management
Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while ...
PipelineReview.com23h
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
JERSEY CITY, NJ, USA I July 7, 2025 I Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing ...